Shanghai Pharmaceuticals Holding to Receive 50.1% in Joint Venture with Biocad


18 September 2019
TASS

Shanghai Pharmaceuticals Holding, an investment holding company, will receive 50.1% in a joint venture with Russian pharmaceutical company Biocad. The parties signed a final agreement on the establishment of a company with the aim of bringing innovative medicines made in Russia to the foreign market, the Biocad press service told TASS on Wednesday.